Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Tafamidis
Drug ID BADD_D02107
Description Tafamidis and tafamidis meglumine (FX-1006A) are benzoxazole derivatives[A27206] developed by FoldRX.[A189717] Tafamidis is structurally similar to diflusinal.[A189717] Tafamidis was granted an EMA market authorisation on 16 November 2011[L6247] and FDA approval on 3 May 2019.[L11280]
Indications and Usage Tafamidis is indicated to treat cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis in adults.[A189708,A189711,L11280]
Marketing Status approved; investigational
ATC Code N07XX08
DrugBank ID DB11644
KEGG ID D09673
MeSH ID C547076
PubChem ID 11001318
TTD Drug ID D04DFR
NDC Product Code 60715-0647; 59651-743; 66039-960; 73435-031; 14501-0102; 58159-079; 60715-4344; 0069-8730; 11014-0390; 69988-0039
UNII 8FG9H9D31J
Synonyms tafamidis | Vyndamax | Vyndaqel | FX 1006A | FX1006A | FX-1006A | tafamidis meglumine
Chemical Information
Molecular Formula C14H7Cl2NO3
CAS Registry Number 594839-88-0
SMILES C1=CC2=C(C=C1C(=O)O)OC(=N2)C3=CC(=CC(=C3)Cl)Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Deafness neurosensory17.04.07.001; 04.02.01.0020.000808%Not Available
Death08.04.01.0010.207802%
Decreased activity19.11.01.002; 08.01.01.0060.001454%Not Available
Dementia17.03.01.001; 19.20.02.0010.002153%Not Available
Dementia Alzheimer's type19.20.03.001; 17.03.06.0010.000808%Not Available
Dermatitis23.03.04.0020.001184%Not Available
Diabetes mellitus14.06.01.001; 05.06.01.0010.001346%Not Available
Diabetic neuropathy17.09.04.002; 14.07.04.003; 05.07.04.0030.000538%Not Available
Diarrhoea07.02.01.001--
Diffuse large B-cell lymphoma16.28.02.001; 01.15.02.0010.000538%Not Available
Dilatation atrial02.04.02.0190.000538%Not Available
Diverticulum intestinal07.10.01.0020.000538%Not Available
Dizziness02.11.04.006; 24.06.02.007; 17.02.05.0030.028586%
Dizziness postural02.11.04.008; 24.06.02.008; 17.02.05.0040.004468%Not Available
Dysphagia07.01.06.0030.034508%
Dyspnoea02.11.05.003; 22.02.01.0040.071762%
Dyspnoea exertional02.11.05.005; 22.02.01.0050.022018%Not Available
Dyspnoea paroxysmal nocturnal02.11.05.006; 22.02.01.0180.000808%Not Available
Ear disorder04.03.01.0010.001184%Not Available
Eating disorder19.09.01.008; 14.03.01.0080.001454%Not Available
Embolic stroke24.01.04.010; 17.08.01.0320.000808%Not Available
Emphysema22.01.02.0020.000808%Not Available
Essential hypertension24.08.02.0080.006999%Not Available
Eyelid ptosis17.17.02.004; 06.05.01.0020.000538%Not Available
Failure to thrive19.07.05.001; 18.04.01.003; 14.03.02.0080.000538%Not Available
Fatigue08.01.01.0020.064979%
Flatulence07.01.04.0020.003661%
Fluid retention20.01.02.003; 14.05.06.0020.010013%Not Available
Gait disturbance15.03.05.013; 17.02.05.016; 08.01.02.0020.013082%
Gastric polyps16.05.03.001; 07.20.01.0030.000538%Not Available
The 3th Page    First    Pre   3 4 5 6 7    Next   Last    Total 10 Pages